Fundamental Data for MITI

Micromet, Inc. is a biopharmaceutical company with a focus on the development of novel, proprietary antibody-based products for cancer and inflammatory and autoimmune diseases. Two product candidates are currently in clinical trials. Micromet has established a drug development platform based on its BiTE technology, a unique, antibody-based format that leverages the cytotoxic potential of T cells, the most powerful ''killer cells'' of the human immune system. Micromet has established collaborations with MedImmune, Inc. and Serono.

# Employees: 94

Address: 6707 Democracy Boulevard Suite 505,Bethesda,MD,USA

Phone: 240-752-1420

Fax: 240-752-1425

Website: www.micromet.de

Email: info@micromet-inc.com

Sector: Medical

Industry: MED-BIOMED/GENE

Executive Officers

David F. Hale (Chmn.; Dir.)

Christian Itin (Presi.; C.E.O.; Dir.)

Donald A. Zelm (C.F.O; Princ. Acctg. Off.)

Jerry C. Benjamin (Dir.)

John E. Berriman (Dir.,)

Dividend

Ex-Dividend Date: N/A

Annual Dividend: N/A

Current Dividend Yield: N/A

Dividend Paid (3 months): N/A

Indicated Dividend: N/A

Earnings

Last Earnings Date: 9/30/2009

Next Earnings Date(Expected): 3/11/2010

Mean EPS (Next Qtr): ($0.18)

Mean EPS (Year): ($0.76)

Mean Estimate(Long Term): ($0.01)

P/E Ratio(Based on EPS estimate): -0.010

Number of Estimates: 5

Shares Performance

Period	MITI	Compare to S&P
YTD	58.26 %	30.98 %
4 Weeks	31.18 %	29.76 %
12 Weeks	4.23 %	-1.73 %

Shares Information

Analyst Coverage: Y

Avg Volume: 338473

Shares Outstanding: 68M

Market Cap: $0.47B

52 Week High: $8.29

52 Week Low: $2.44

P/E Ratio: -0.010

PEG Ratio: -0.010

Split: On 5/8/2006 MITI split by factor of 0.330

Earnings Performance

EPS Growth in Last Quarter: -46.67 %

EPS Growth in Last Year: -46.67 %

Sales Growth in Last Quarter: -18.44 %

Sales Growth in Last Quarter: -42.87 %

Financials

Qtr Book Value: $5.36

Cash Flow/Share: ($0.01)

Change in Payout Ratio: -0.010

Price/Sales: 21.920